Brief: Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO in Liver-Dominant Metastatic Colorectal Cancer
02/12/2024 13:40
Dec 2 (Reuters) - Delcath Systems Inc DCTH.O :
* DELCATH SYSTEMS ANNOUNCES FDA CLEARANCE OF IND APPLICATION
FOR
PHASE 2 CLINICAL TRIAL OF HEPZATO™ IN LIVER-DOMINANT METASTATIC
COLORECTAL CANCER
* DELCATH SYSTEMS INC - PRIMARY ENDPOINT DATA EXPECTED BY
END OF
2027
* DELCATH SYSTEMS INC: OVERALL SURVIVAL, SECONDARY ENDPOINT,
IS
EXPECTED IN 2028
Source text: ID:nBw4PjpXa
Further company coverage: DCTH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Delcath Systems
See all newsBrief: Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Delcath Systems Q1 revenue beats on Hepzato growth
Brief: Delcath Systems Announces Publication Of Chopin Clinical Trial Results In The Lancet Oncology
Delcath Q4 revenue rises 37%, beats estimates
Brief: Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)